InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update -November 06, 2023 at 07:02 am EST
- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption clinical trial demonstrating an overall major adverse events rate of 0.95% from procedure...
United States Patrick Verta Shane Gleason Chuck Padala Marvin Slosman National Coverage Determination
Source: marketscreener.com